To date, the most promising proposed serum biomarkers (i.e.: cytokeratin-18 M30 fragment [8], fibroblast growth factor 21 [35], interleukin 1 receptor antagonist [36], pigment epithelium-derived factor [11], osteoprotegerin [37]), showed a potential in diagnosing NAFLD and NASH. Here, TNFRSF11B is linked to metabolic dysfunction-associated steatohepatitis.